Cargando…
Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834538/ https://www.ncbi.nlm.nih.gov/pubmed/33359911 http://dx.doi.org/10.1016/j.phrs.2020.105402 |
| _version_ | 1783642304057180160 |
|---|---|
| author | Di Maria, Emilio Martini, Paolo Gennarelli, Massimo |
| author_facet | Di Maria, Emilio Martini, Paolo Gennarelli, Massimo |
| author_sort | Di Maria, Emilio |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7834538 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-78345382021-01-26 Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19 Di Maria, Emilio Martini, Paolo Gennarelli, Massimo Pharmacol Res Letter to the Editor Elsevier Ltd. 2021-02 2020-12-24 /pmc/articles/PMC7834538/ /pubmed/33359911 http://dx.doi.org/10.1016/j.phrs.2020.105402 Text en © 2021 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Di Maria, Emilio Martini, Paolo Gennarelli, Massimo Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19 |
| title | Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19 |
| title_full | Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19 |
| title_fullStr | Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19 |
| title_full_unstemmed | Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19 |
| title_short | Naringerin as candidate drug against SARS-CoV-2: The role for TPC2 genomic variants in COVID-19 |
| title_sort | naringerin as candidate drug against sars-cov-2: the role for tpc2 genomic variants in covid-19 |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7834538/ https://www.ncbi.nlm.nih.gov/pubmed/33359911 http://dx.doi.org/10.1016/j.phrs.2020.105402 |
| work_keys_str_mv | AT dimariaemilio naringerinascandidatedrugagainstsarscov2therolefortpc2genomicvariantsincovid19 AT martinipaolo naringerinascandidatedrugagainstsarscov2therolefortpc2genomicvariantsincovid19 AT gennarellimassimo naringerinascandidatedrugagainstsarscov2therolefortpc2genomicvariantsincovid19 |